JP2019509265A - 二重標的化によるアデノウイルスの皮下送達 - Google Patents
二重標的化によるアデノウイルスの皮下送達 Download PDFInfo
- Publication number
- JP2019509265A JP2019509265A JP2018541394A JP2018541394A JP2019509265A JP 2019509265 A JP2019509265 A JP 2019509265A JP 2018541394 A JP2018541394 A JP 2018541394A JP 2018541394 A JP2018541394 A JP 2018541394A JP 2019509265 A JP2019509265 A JP 2019509265A
- Authority
- JP
- Japan
- Prior art keywords
- tumor
- patient
- epitope
- cells
- associated epitope
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001111—Immunoglobulin superfamily
- A61K39/001114—CD74, Ii, MHC class II invariant chain or MHC class II gamma chain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/235—Adenoviridae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/32—T-cell receptors [TCR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4201—Neoantigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/428—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70532—B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/06—Fusion polypeptide containing a localisation/targetting motif containing a lysosomal/endosomal localisation signal
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10041—Use of virus, viral particle or viral elements as a vector
- C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Toxicology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- General Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Developmental Biology & Embryology (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662294251P | 2016-02-11 | 2016-02-11 | |
| US62/294,251 | 2016-02-11 | ||
| US201662294987P | 2016-02-12 | 2016-02-12 | |
| US62/294,987 | 2016-02-12 | ||
| PCT/US2017/017588 WO2017139725A1 (en) | 2016-02-11 | 2017-02-12 | Subcutaneous delivery of adenovirus with dual targeting |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019509265A true JP2019509265A (ja) | 2019-04-04 |
| JP2019509265A5 JP2019509265A5 (cg-RX-API-DMAC7.html) | 2020-03-19 |
Family
ID=59563571
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018541394A Pending JP2019509265A (ja) | 2016-02-11 | 2017-02-12 | 二重標的化によるアデノウイルスの皮下送達 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20190091316A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3413909A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2019509265A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20180102707A (cg-RX-API-DMAC7.html) |
| CN (1) | CN109069598A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2017218445A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3014056A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL261037A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2017139725A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3735984A1 (en) * | 2016-05-27 | 2020-11-11 | Etubics Corporation | Neoepitope vaccine compositions and methods of use thereof |
| KR20210010678A (ko) | 2016-06-30 | 2021-01-27 | 난트 홀딩스 아이피, 엘엘씨 | 난트 암 백신 |
| US12653874B2 (en) | 2016-06-30 | 2026-06-16 | Immunitybio, Inc. | Nant cancer vaccine |
| AU2017305396A1 (en) * | 2016-08-02 | 2019-02-21 | Nant Holdings Ip, Llc | Transfection of dendritic cells and methods therefor |
| US11839655B2 (en) | 2017-09-01 | 2023-12-12 | Microvax, Llc | Combination cancer therapy |
| GB201804468D0 (en) * | 2018-03-21 | 2018-05-02 | Valo Therapeutics Oy | PeptiCRAd Cancer Therapy |
| US11823773B2 (en) | 2018-04-13 | 2023-11-21 | Nant Holdings Ip, Llc | Nant cancer vaccine strategies |
| EP3827262A1 (en) | 2018-07-26 | 2021-06-02 | Frame Pharmaceuticals B.V. | Cancer vaccines for breast cancer |
| WO2020022897A1 (en) | 2018-07-26 | 2020-01-30 | Frame Pharmaceuticals B.V. | Method of preparing subject-specific immunogenic compositions based on a neo open-reading-frame peptide database |
| US20220133823A1 (en) * | 2018-09-10 | 2022-05-05 | Genesail Biotech (Shanghai) Co. Ltd. | A modified oncolytic virus, composition and use thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006506072A (ja) * | 2002-11-12 | 2006-02-23 | デイッセロース,アルバート,ビー | アデノウイルスベクターワクチン |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2404689T3 (es) * | 2001-04-05 | 2013-05-28 | The Johns Hopkins University | Vacunas quiméricas que comprenden el dominio lumenal de LAMP-1 o LAMP-2 |
| FR2993716B1 (fr) * | 2012-07-20 | 2016-09-02 | Thales Sa | Antenne d'emission et de reception multifaisceaux a plusieurs sources par faisceau, systeme d'antennes et systeme de telecommunication par satellite comportant une telle antenne |
| AU2013296919A1 (en) * | 2012-07-30 | 2015-01-22 | Alex Wah Hin Yeung | Cancer vaccine comprises tumor cells, an oncolytic virus vector and/or an immune checkpoint modulator |
| AU2014251207B2 (en) * | 2013-04-07 | 2019-06-13 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for personalized neoplasia vaccines |
| US11149087B2 (en) * | 2015-04-20 | 2021-10-19 | Etubics Corporation | Methods and compositions for combination immunotherapy |
-
2017
- 2017-02-12 EP EP17750935.3A patent/EP3413909A4/en not_active Withdrawn
- 2017-02-12 AU AU2017218445A patent/AU2017218445A1/en not_active Abandoned
- 2017-02-12 KR KR1020187026204A patent/KR20180102707A/ko not_active Ceased
- 2017-02-12 CA CA3014056A patent/CA3014056A1/en not_active Abandoned
- 2017-02-12 CN CN201780011041.2A patent/CN109069598A/zh active Pending
- 2017-02-12 JP JP2018541394A patent/JP2019509265A/ja active Pending
- 2017-02-12 WO PCT/US2017/017588 patent/WO2017139725A1/en not_active Ceased
- 2017-02-12 US US16/075,874 patent/US20190091316A1/en not_active Abandoned
-
2018
- 2018-08-07 IL IL261037A patent/IL261037A/en unknown
-
2021
- 2021-08-30 US US17/461,319 patent/US20210386844A1/en not_active Abandoned
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006506072A (ja) * | 2002-11-12 | 2006-02-23 | デイッセロース,アルバート,ビー | アデノウイルスベクターワクチン |
Non-Patent Citations (3)
| Title |
|---|
| CYTOTHERAPY, vol. 14, JPN6021003650, 2012, pages 830 - 840, ISSN: 0004607864 * |
| IMMUNOLOGY, vol. 122, JPN6021003651, 2007, pages 522 - 531, ISSN: 0004607866 * |
| NATURE REVIEWS DRUG DISCOVERY, vol. 14, no. 7, JPN6021003649, 2015, pages 487 - 498, ISSN: 0004607865 * |
Also Published As
| Publication number | Publication date |
|---|---|
| IL261037A (en) | 2018-10-31 |
| CN109069598A (zh) | 2018-12-21 |
| KR20180102707A (ko) | 2018-09-17 |
| WO2017139725A1 (en) | 2017-08-17 |
| US20210386844A1 (en) | 2021-12-16 |
| CA3014056A1 (en) | 2017-08-17 |
| EP3413909A4 (en) | 2019-10-30 |
| EP3413909A1 (en) | 2018-12-19 |
| AU2017218445A1 (en) | 2018-08-23 |
| US20190091316A1 (en) | 2019-03-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230293651A1 (en) | Iterative Discovery Of Neoepitopes And Adaptive Immunotherapy And Methods Therefor | |
| US20200297830A1 (en) | Sequence arrangements and sequences for neoepitope presentation | |
| US20210386844A1 (en) | Subcutaneous Delivery of Adenovirus with Dual Targeting | |
| US12311018B2 (en) | Targeted neoepitope vectors and methods therefor | |
| US20200282032A1 (en) | Neoepitope vaccine compositions and methods of use thereof | |
| JP7034931B2 (ja) | ネオエピトープのウイルス送達のための改善された組成物および方法ならびにその使用 | |
| JP2019524773A (ja) | 樹状細胞のトランスフェクション及びその方法 | |
| KR20200055136A (ko) | Th1 및 Th2를 자극하는 다가 항원 (MULTIVALENT ANTIGENS STIMULATING TH1 AND TH2) | |
| HK1258092B (en) | Iterative discovery of neoepitopes and adaptive immunotherapy and methods therefor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200206 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200206 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210209 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20211005 |